Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Arbeitsgemeinschaft medikamentoese Tumortherapie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically verified diagnosis if MALT lymphoma of any localization
Measurable disease upon diagnosis or first or greater relapse after local therapy, prior chemotherapy orHP-eradication. In addition, also in patients with gastric MALT-lymphoma judged refractory to HP-eradication by a minimum follow-up of 12 months after successfulHP-eradication will be included in the study. Patients with gastric MALT lymphoma and no evidence of HP-infection may be enrolled immediately
Ann Arbor Stage I-IV
In case of prior treatment with Rituximab, the presence of CD20 on lymphoma cells must have been demonstrated before inclusion in the trial.
ECOG performance status of 0,1 or 2
Patient must be able to take aspirin daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin
You may not be if
Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") - component
Use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide
History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years
Major surgery, other than diagnostic surgery, within the last 4 weeks
Evidence of CNS involvement
A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
Severe peripheral polyneuropathy
Clinically significant cardiac disease or myocardial infarction within the last 6 months
Known hypersensitivity to thalidomide or lenalidomide or rituximab
Clareo Health | Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
